Takeda Pharmaceuticals has announced that it will invest more than EUR 100 million ($106 million) to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Initial construction activities will start immediately, and the facility is expected to be ready for production in 2019. Takeda said its colleagues in Singen have experience with lyophilization technology, which is used in the manufacturing process for Takeda’s dengue vaccine finished product.

Takeda’s tetravalent dengue vaccine candidate, TAK-003, is based on a live-attenuated dengue serotype 2 virus and is being developed for populations and individuals at risk for dengue across geographies, whether or not they have had previous exposure to dengue virus, including children and adults, travelers, and those living in endemic areas.

Source: Takeda Pharmaceuticals